Catalent invests US$20m to boost inhalation services
Will expand pMDI capabilities at Research Triangle Park, NC, US
Catalent Pharma Solutions is to invest US$20m to expand its pressurised Metered Dose Inhaler (pMDI) clinical and commercial supply capabilities at its Inhalation Center of Excellence at Research Triangle Park in North Carolina, US.
The company says it will also make other enhancements to the facility.
Catalent provides a range of inhalation services including API optimisation, pre-formulation, formulation, analytical testing and manufacturing across all inhaled dosage forms at the North Carolina facility, and at its advanced aseptic development and fill/finish supply solutions facility in Woodstock, Illinois.
‘Catalent’s investment in commercial manufacturing at our Inhalation Center of Excellence not only fits with our advanced drug delivery growth strategy, but also positions us as a world leader supporting inhaled products,’ said Scott Houlton, president of Catalent’s Development and Clinical Services business.
‘In addition to the introduction of scalable processes for micro-dosing inhalation powder formulations, and the recent commissioning of our new nasal filling suite, this investment will upgrade our pMDI manufacturing capacity and allow us better to support our customers from early development all the way through to commercialisation; bringing more products and better treatments to market faster.’
